Skip to content
OpenCapital
Get started

United Therapeutics UTHR Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$781.5MMiss by $15.9MDiluted EPS$5.82Miss by $1.18
Revenue estimate$797.4M
EPS estimate$7.00

Next report

Jul 29, 2026 (In 5 days)
Revenue estimate$805.0M
EPS estimate$7.06

Financials

Q1 2026

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation & ratios

Valuation

as of 07/23/26
See full
Market cap$26.25B+90.4%
P/E20.4×+9.3×
P/S8.3×+3.8×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Current ratio4.8×-0.7×

Segments

By product

See full
Tyvaso DPI$330.3M+9.2%
Orenitram$135.6M+12.3%
Nebulized Tyvaso$127.2M-22.3%
Remodulin$126.6M-8.4%
Unituxin$53.6M-7.9%

Versus estimates

Revenue

Q1 2026$781.5MMiss by $15.9M
Q4 2025$790.2MMiss by $22.9MQ3 2025$799.5MMiss by $15.3MQ2 2025$798.6MMiss by $3.3MQ1 2025$794.4MBeat by $15.7MQ4 2024$735.9MBeat by $1.2M

Diluted EPS

Q1 2026$5.82Miss by $1.18
Q4 2025$7.70Beat by $0.57Q3 2025$7.16Beat by $0.27Q2 2025$6.41Miss by $0.88Q1 2025$6.63Beat by $0.34Q4 2024$6.19Miss by $0.21

Ask the moment United Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did United Therapeutics report Q1 2026 earnings?
United Therapeutics (UTHR) reported Q1 2026 earnings on May 6, 2026 before market open.
What were United Therapeutics's Q1 2026 revenue and EPS?
United Therapeutics reported revenue of $781.5M and diluted EPS of $5.82 for Q1 2026.
Did United Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $797.4M by $15.9M. EPS missed the consensus estimate of $7.00 by $1.18.
How did United Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.6% from $794.4M a year earlier and diluted EPS declined 12.2% from $6.63.
Where can I find United Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001082554-26-000021) and the 10-Q periodic report (0001082554-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.